OS Analysis of OBSCN and AHNAK2 mutations in integrated GBM datasets and their association with clinical factors.

a) The Kaplan-Meier curve for OS analysis in OBSCN mutant and wild-type (Wt) GBM patients. b) The Kaplan-Meier curve for OS analysis in AHNAK2 mutant and wild-type (WT) GBM patients c) Univariate Cox regression analysis for OBSCN and/or AHNAK2 mutations versus wild-type GBM patients. d) The Kaplan-Meier curve for GBM patients with OBSCN and AHNAK2 double mutations (Double-Mut) compared to Single-Mut and Double-WT phenotypes. e) TMB levels in Double-WT, Single-Mut and Double-Mut phenotypes based on OBSCN and AHNAK2 statuses. f) The number of GBM patients with AHNAK2 mutation or wild-type status concerning age, gender, and IDH1 mutational status. g) The number of GBM patients with OBSCN mutation or wild-type status concerning age, gender, and IDH1 status. h) The number of GBM patients with OBSCN and AHNAK2 Double-Mut, Single-Mut, and wild-type phenotypes concerning age, gender, and IDH1 status.